Skip to main content
Mabpharm Limited logo

Mabpharm Limited — Investor Relations & Filings

Ticker · 2181 ISIN · KYG5780F1046 HKEX Manufacturing
Open in API
Filings indexed 221 across all filing types
Latest filing 2020-05-25 AGM Information
Country HK Hong Kong
Listing HKEX 2181

About Mabpharm Limited

http://www.mabpharm.cn

Mabpharm Limited is a biopharmaceutical company focused on the research, development, production, and commercialization of monoclonal antibody (mAb) drugs and biosimilars. The core therapeutic areas include oncology (cancer) and autoimmune diseases. The company emphasizes bringing high-quality, affordable, and innovative biological drugs to the market by utilizing efficient R&D systems and low-cost manufacturing capabilities. Its robust pipeline features multiple candidates, including 9 monoclonal antibody drugs and 1 strong antibody drug.

Recent filings

Filing Released Lang Actions
PROPOSED RE-ELECTION OF DIRECTORS PROPOSED CHANGE OF AUDITOR PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a circular from Mabpharm Limited to its shareholders regarding the upcoming Annual General Meeting (AGM). It includes detailed information about the proposed re-election of directors, change of auditor, granting of general mandates to repurchase and issue shares, and the notice of the AGM itself. The content is typical of materials sent to shareholders to inform them about the AGM agenda and related proposals, including proxy arrangements and explanatory statements. This type of document is classified as AGM Information (AGM-R) because it is the presentation and materials shared for the AGM, not the actual minutes or results of the meeting, nor a financial report or regulatory filing. The document length and detail confirm it is not a brief announcement but a full circular for the AGM.
2020-05-25 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a Notice of Annual General Meeting (AGM) for Mabpharm Limited, detailing the date, time, venue, and agenda items for the meeting. It includes resolutions to be voted on, such as re-election of directors, appointment of auditors, and mandates for share repurchase and issuance. The document does not contain actual financial statements or detailed financial analysis but serves as a formal announcement to shareholders about the upcoming AGM and the matters to be considered. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or notices related to it.
2020-05-25 English
PROPOSED CHANGE OF AUDITOR
Audit Report / Information Classification · 95% confidence The document is an announcement regarding a proposed change of auditor for Mabpharm Limited. It references the retirement of the current auditor Deloitte and the proposed appointment of Ernst & Young, subject to shareholder approval at the upcoming AGM. The document is relatively short (3060 characters) and does not contain any financial statements or audit results. It is a regulatory announcement about auditor change, not the audit report itself. Therefore, it fits best under the category of Audit Report / Information (AR) as it relates to auditor matters but is not a full audit report or annual report.
2020-05-20 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions for the month ended 30/04/2020. The content is focused on share capital changes, share issuance, and related confirmations. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is a regulatory filing reporting share capital movements and related confirmations to the stock exchange, consistent with a Major Shareholding Notification or Share Issue/Capital Change. However, since it reports detailed movements in securities and share capital, it aligns best with Share Issue/Capital Change filings. The document is substantive and not merely an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2020-05-06 English
2019 Annual Report
Regulatory Filings
2020-04-24 English
CLARIFICATION ANNOUNCEMENT IN RELATION TO ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2019
Regulatory Filings Classification · 95% confidence The document is titled as a "Clarification Announcement in Relation to Annual Results Announcement for the Year Ended December 31, 2019". It references an earlier "Annual Results Announcement" dated March 27, 2020, and provides corrections to the "Use of Net Proceeds from Listing" section of that announcement. The document is relatively short (4295 characters) and primarily serves to clarify and amend information previously disclosed in the Annual Results Announcement. It does not contain full financial statements or comprehensive financial performance data itself, but rather an update or correction to a prior announcement. This fits the pattern of a Regulatory Filing (RNS) as it is an announcement clarifying previously released information rather than the full annual report or earnings release itself.
2020-04-13 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.